Bioventus Inc. (BVS)
Nasdaq · Healthcare · Medical Devices
$13.52+2.97%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $924M
- P/E (trailing)
- 17.3
- Forward P/E
- 14.7
- 52-week range
- $6.37 – $15.89
- 52-week change
- +97.44%
- EPS (trailing)
- $0.78
- Next earnings
- Nov 3, 2026
Fiscal year to Dec 2025
- Revenue
- $568M (−0.91%)
- Net income
- $22.7M
- Operating margin
- 9.5%
- Diluted EPS
- $0.33
- Free cash flow
- $72.1M
From the company’s annual report on SEC EDGAR.
About Bioventus Inc.
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion.
Headquarters: Durham, United States · 950 employees · bioventus.com